Pregled bibliografske jedinice broj: 1280912
Development of an exoglycosidase plate-based assay for detecting alpha 1-3,4 fucosylation biomarker in individuals with HNF1A-MODY
Development of an exoglycosidase plate-based assay for detecting alpha 1-3,4 fucosylation biomarker in individuals with HNF1A-MODY // Glycobiology, 32 (2021), 3; 230-238 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1280912 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Development of an exoglycosidase plate-based assay
for detecting alpha 1-3,4 fucosylation biomarker
in individuals with HNF1A-MODY
Autori
Demus, Daniel ; Jansen, Bas C. ; Gardner, Richard A. ; Urbanowicz, Paulina A. ; Wu, Haiyang ; Stambuk, Tamara ; Juszczak, Agata ; Medvidovic, Edita Pape ; Juge, Nathalie ; Gornik, Olga ; Owen, Katharine R. ; Spencer, Daniel I. R.
Izvornik
Glycobiology (0959-6658) 32
(2021), 3;
230-238
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
biomarker ; diabetes ; fucosylation ; glycans ; hnf1a-mody
Sažetak
Maturity-onset diabetes of the young due to hepatocyte nuclear factor-1 alpha variants (HNF1A- MODY) causes monogenic diabetes. Individuals carrying damaging variants in HNF1A show decreased levels of alpha 1-3, 4 fucosylation, as demonstrated on antennary fucosylation of blood plasma N-glycans. The excellent diagnostic performance of this glycan biomarker in blood plasma N-glycans of individuals with HNF1A-MODY has been demonstrated using liquid chromatography methods. Here, we have developed a high-throughput exoglycosidase plate-based assay to measure alpha 1-3, 4 fucosylation levels in blood plasma samples. The assay has been optimized and its validity tested using 1000 clinical samples from a cohort of individuals with young-adult onset diabetes including cases with HNF1A-MODY. The alpha 1-3, 4 fucosylation levels in blood plasma showed a good differentiating power in identifying cases with damaging HNF1A variants, as demonstrated by receiver operating characteristic curve analysis with the AUC values of 0.87 and 0.95. This study supports future development of a simple diagnostic test to measure this glycan biomarker for application in a clinical setting.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac,
GENOS d.o.o.
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE